Iga Serafin

Ms. Iga Serafin


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
David AebisherDavid Aebisher
David Aebisher
ISIga Serafin
Iga Serafin
KBKatarzyna Batóg-Szczęch
Katarzyna Batóg-Szczęch
KDKlaudia Dynarowicz
Klaudia Dynarowicz
Ewa ChodurekEwa Chodurek
Ewa Chodurek
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher
Photodynamic therapy (PDT) is a promising cancer treatment method that uses photosensitizing (PS) compounds to selectively destroy tumor cells using laser light. This review discusses the main advantages of PDT, such as its low invasiveness, minimal systemic toxicity and low risk of complications. Special attention is paid to photosensitizers obtained by chemical synthesis. Three generations of photosensitizers are presented, starting with the first, based on porphyrins, through the second generation, including modified porphyrins, chlorins, 5-aminolevulinic acid (ALA) and its derivative hexyl aminolevulinate (HAL), to the third generation, which is based on the use of nanotechnology to increase the selectivity of therapy. In addition, current research trends are highlighted, including the search for new photosensitizers that can overcome the limitations of existing therapies, such as heavy-atom-free nonporphyrinoid photosensitizers, antibody–drug conjugates (ADCs) or photosensitizers with a near-infrared (NIR) absorption peak. Finally, the prospects for the development of PDTs are presented, taking into account advances in nanotechnology and biomedical engineering. The references include both older and newer works. In many cases, when writing about a given group of first- or second-generation photosensitizers, older publications are used because the properties of the compounds described therein have not changed over the years. Moreover, older articles provide information that serves as an introduction to a given group of drugs.

14 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher
RPRafał Podgórski
Rafał Podgórski
ISIga Serafin
Iga Serafin
David AebisherDavid Aebisher
David Aebisher
Atherosclerosis, a chronic inflammatory disease, remains a leading cause of cardiovascular mortality worldwide. Despite standard treatments like statins and percutaneous coronary intervention (PCI), significant residual risk and therapeutic limitations underscore the need for innovative strategies. This review summarizes recent advances in nanoparticle-based therapies for atherosclerosis, focusing on key developments from the last five years. We discuss various nanoplatforms designed to selectively target key cellular players in plaque pathogenesis, including macrophages, endothelial cells, and vascular smooth muscle cells (VSMCs), to inhibit inflammation, modulate cellular phenotypes, and stabilize plaques. A significant focus is placed on the emerging field of biomimetic nanoparticles, where therapeutic cores are camouflaged with cell membranes derived from macrophages, platelets, neutrophils, or erythrocytes. This approach leverages the natural biological functions of the source cells to achieve enhanced immune evasion, prolonged circulation, and precise targeting of atherosclerotic lesions. Furthermore, the review covers nanoparticles engineered for specific functional interventions, such as lowering LDL levels and exerting direct anti-inflammatory and anti-oxidative effects. Finally, we address the critical challenges hindering clinical translation, including nanotoxicity, biodistribution, and manufacturing scalability. In conclusion, nanotechnology offers a versatile and powerful platform for atherosclerosis therapy, with targeted and biomimetic strategies holding immense promise to revolutionize future cardiovascular medicine.

9 June 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
David AebisherDavid Aebisher
David Aebisher
ISIga Serafin
Iga Serafin
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher
Continuous progress in dentistry and orthodontics is crucial to ensuring high-quality diagnosis and treatment of patients, especially since malocclusions occur in up to half of the population. In addition to limiting the physiological functions of the masticatory system, they are often an aesthetic defect that may directly affect the well-being and even self-esteem of patients, especially in their teenage years and early adulthood. A holistic model of perceiving and treating orthodontic diseases, such as the Biocreative Orthodontic Strategy, focusing not only on the correction of the defect itself but also taking into account the least possible interference in the physiology of the masticatory system, limiting the use of appliances to a minimum, and taking into account the patient’s preferences, is a special alternative to conventional therapeutic models. In this review, we are presenting the current knowledge regarding the applications of temporary skeletal anchorage devices (TSAD) and cone beam computed tomography (CBCT) in orthodontics.